Neogenomics vs Repligen
Neogenomics and Repligen are similar in size: $727m and $738m of revenue in their latest fiscal years. Repligen grew faster (16.4% against 10.1%). Repligen kept more of each dollar of sales as profit: a net margin of 6.6% against -14.9%.
| Latest fiscal year | NeogenomicsNEO, 2025 | RepligenRGEN, 2025 |
|---|---|---|
| Revenue | $727m | $738m |
| Revenue growth | 10.1% | 16.4% |
| Net income | −$108m | $48.9m |
| Operating margin | — | 7.5% |
| Net margin | -14.9% | 6.6% |
| Return on equity | -12.4% | 2.4% |
| Free cash flow | −$21.8m | $93.9m |
| Cash | $160m | $566m |
| Total debt | $345m | $542m |
| Debt to equity | — | 25.7% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | 2,500 | 2,000 |
| Market value | $2.20bn | $10.13bn |
| Price vs our value range | — | Above our value range |
| Moat score | 34 (Weak) | 39 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 25 sales |